Last updated: October 5, 2026
Pepcid AC is an over-the-counter famotidine product marketed primarily by Kenvue in the United States. Its commercial position rests on brand recognition, broad retail distribution, and the permanent loss of compound exclusivity rather than on enforceable patent barriers. Generic famotidine, private-label products, and competing proton-pump inhibitors limit pricing power. Kenvue does not publicly disclose Pepcid AC revenue as a standalone line item, so the brand’s financial trajectory must be assessed through category trends, corporate segment results, retail activity, and demand events.
What is Pepcid AC and who owns the brand?
Pepcid AC contains famotidine, an H2-receptor antagonist that reduces gastric acid secretion. The standard U.S. product is labeled for relief and prevention of heartburn associated with acid indigestion.[1]
Kenvue is the current consumer-health owner and marketer of the Pepcid brand in the United States. Kenvue was separated from Johnson & Johnson in 2023 and owns a portfolio that includes Tylenol, Motrin, Neutrogena, Listerine, Zyrtec, and Pepcid.[2]
| Item |
Current position |
| Brand |
Pepcid AC |
| Active ingredient |
Famotidine |
| Drug category |
OTC H2-receptor antagonist |
| Primary indication |
Heartburn and acid indigestion |
| U.S. brand owner |
Kenvue |
| Original prescription developer |
Merck, with historical development involving Yamanouchi |
| Current regulatory route |
OTC monograph-based marketing |
| Prescription Orange Book status |
Not the principal regulatory framework for the OTC product |
| Main competitors |
Generic famotidine, store brands, omeprazole, esomeprazole, lansoprazole, calcium carbonate products |
| Dosage forms |
Tablets, chewable tablets, and combination products, depending on market and package |
Pepcid AC is distinct from Pepcid Complete, which combines famotidine with antacids. Kenvue markets multiple Pepcid formats and strengths, including products positioned for rapid relief, longer-duration relief, or prevention of heartburn.
What is the FDA regulatory status of Pepcid AC?
Pepcid AC is an OTC product governed primarily by the FDA’s nonprescription drug framework rather than by an active new-drug approval strategy. Famotidine is included within FDA requirements for OTC antacid and acid-reducer products, including labeling, dosage, warnings, and permitted active ingredients.[3]
The OTC regulatory model reduces the importance of product-by-product approval exclusivity. A competing manufacturer can market famotidine if its product conforms to the applicable monograph requirements or receives separate FDA authorization.
Is Pepcid AC listed in the Orange Book?
Pepcid AC does not have the same Orange Book exclusivity profile as a currently protected prescription drug. The FDA Orange Book is principally used to identify approved prescription drug products, therapeutic equivalence codes, listed patents, and regulatory exclusivities.[4]
Because Pepcid AC is an OTC monograph product, its commercial protection does not depend on active Orange Book patent listings. Generic and store-brand famotidine products can compete without waiting for expiration of a Pepcid AC brand patent.
What patents protect Pepcid AC?
No active composition-of-matter patent is the principal commercial barrier for Pepcid AC. Famotidine has been available in the United States for decades, and the original product patent period has expired.
Historical famotidine patents covered the chemical compound and related pharmaceutical compositions. The core U.S. patent estate dates to the period before the product’s 1980s launch and cannot block current generic famotidine entry. Any surviving patents would have to relate to a specific formulation, manufacturing process, or delivery configuration rather than the famotidine molecule itself.
| Patent category |
Commercial status for Pepcid AC |
| Famotidine composition patent |
Expired |
| Basic tablet formulation patents |
Expired or commercially non-blocking |
| OTC monograph protection |
No exclusivity period comparable to a new-drug patent |
| Brand packaging and trade dress |
Potential trademark or unfair-competition rights |
| Current Orange Book blocking patent |
No material blocking position identified |
| Generic famotidine entry |
Established |
Brand protection remains possible through the PEPCID trademark, package design, consumer recognition, and retailer relationships. Those rights do not prevent sale of therapeutically equivalent famotidine under another name.
When did Pepcid AC lose exclusivity?
Pepcid AC lost meaningful drug exclusivity when famotidine’s core patents expired and the product moved from prescription use to OTC distribution. The prescription product Pepcid was approved in the 1980s, and the OTC switch occurred in the 1990s. FDA approved nonprescription famotidine products in 1995, allowing the active ingredient to compete in the consumer market.[5]
The relevant timeline is:
| Period |
Event |
| 1980s |
Pepcid prescription product introduced in the United States |
| 1990s |
Famotidine compound and early product patents expired or approached expiration |
| 1995 |
FDA approved OTC Pepcid for heartburn relief |
| 2000s |
Generic and private-label famotidine became established |
| 2019 |
Ranitidine products were withdrawn or suspended after NDMA contamination concerns |
| 2020 |
Famotidine demand increased sharply during COVID-19-related consumer and clinical interest |
| 2023 |
Kenvue became an independent consumer-health company |
| Current |
Pepcid competes in a mature, largely unprotected OTC category |
Pepcid AC therefore has no future patent cliff comparable to a branded prescription medicine. The economic issue is share retention, not loss of a pending patent monopoly.
How strong is the Pepcid AC patent estate?
The patent estate is weak as a barrier to generic entry but strong in brand and distribution terms.
Patent strength
The product has:
- No meaningful active molecule patent blocking famotidine.
- No conventional prescription-style launch exclusivity.
- Limited ability to prevent equivalent generic or private-label products.
- Potential rights in trademarks, packaging, product names, and advertising claims.
- Possible formulation-specific protection for particular combinations or dosage forms, although those rights do not protect the basic famotidine market.
Kenvue’s principal advantages are commercial. Pepcid has longstanding consumer awareness, prominent pharmacy placement, national advertising, and high recognition among heartburn consumers. Those assets can support a premium over store-brand famotidine even when the active ingredient is identical.
What market dynamics affect Pepcid AC?
Pepcid AC operates in a mature gastrointestinal OTC market with several competing treatment mechanisms.
H2 blockers versus proton-pump inhibitors
Famotidine provides relatively rapid acid reduction and is commonly used for intermittent or preventive heartburn. Proton-pump inhibitors such as omeprazole, esomeprazole, and lansoprazole generally have stronger and longer acid suppression but are positioned for more frequent heartburn and longer treatment courses.
Antacids such as calcium carbonate provide faster, shorter relief. Combination products compete by offering rapid antacid action with famotidine’s longer H2-blocker effect.
| Segment |
Representative products |
Competitive effect on Pepcid AC |
| H2 blockers |
Pepcid AC, generic famotidine |
Direct price and shelf competition |
| Proton-pump inhibitors |
Prilosec OTC, Nexium 24HR, Prevacid 24HR |
Compete for frequent-heartburn users |
| Antacids |
Tums, Rolaids, Maalox |
Compete for rapid, episodic relief |
| Combination products |
Pepcid Complete and similar products |
Expand convenience but may increase complexity |
| Store brands |
Retailer-labeled famotidine and acid reducers |
Pressure brand pricing and margins |
The withdrawal of ranitidine materially improved the strategic position of famotidine. FDA requested removal of all ranitidine products from the U.S. market in April 2020 because NDMA levels could increase over time and with storage conditions.[6] Famotidine became the leading widely available H2-blocker substitute, although generic supply and manufacturing capacity constrained availability during periods of increased demand.
COVID-19 demand spike
Famotidine experienced an unusual demand surge in 2020 after preliminary reports examined its possible relationship with COVID-19 outcomes. The reports did not establish famotidine as an approved COVID-19 treatment, and the FDA did not approve Pepcid for that use. The episode nevertheless increased consumer awareness and temporarily affected supply and retail availability.
Demand subsequently normalized. The COVID-related increase was therefore a one-time market event rather than a durable indication expansion.
What is the financial trajectory of Pepcid AC?
Kenvue does not report Pepcid AC revenue, gross margin, or operating profit separately in its public filings. The brand is included within Kenvue’s self-care portfolio, and the company reports broader segment and category results rather than brand-level financial statements.[2]
This limits direct calculation of:
- Pepcid AC annual sales.
- Brand-specific growth rates.
- Standalone gross margin.
- Advertising-to-sales ratios.
- Market share by dosage form.
- U.S. versus international profitability.
The financial trajectory can still be characterized:
- The brand has a mature revenue base.
- Generic competition limits unit pricing.
- Brand equity supports a premium over private-label famotidine.
- Demand benefited from ranitidine’s withdrawal.
- The 2020 COVID-related spike was temporary.
- Growth depends on category expansion, product innovation, pricing, and distribution rather than patent exclusivity.
- Kenvue’s reported self-care performance is the relevant corporate indicator, not a Pepcid-specific revenue figure.
Kenvue’s annual reports identify self-care as one of its principal operating segments and report performance at the segment level. Pepcid’s contribution is economically relevant to the U.S. digestive-health portfolio but is not large enough, or not separately material enough, to receive standalone disclosure in the company’s financial reporting.[2]
Revenue exposure
Pepcid’s revenue exposure is concentrated in:
- U.S. retail pharmacies.
- Mass merchants and grocery stores.
- E-commerce channels.
- Seasonal and episodic heartburn demand.
- Brand-switching after ranitidine withdrawal.
- Consumer preference for short-duration, as-needed therapy.
The brand is less exposed to reimbursement formularies than prescription medicines. Its performance depends more on shelf placement, retailer promotions, package configuration, consumer advertising, and out-of-pocket price.
Which companies challenge Pepcid AC?
Pepcid AC faces competition from branded and unbranded manufacturers.
Direct famotidine competitors
Major competitive sources include:
- CVS Health and other pharmacy private labels.
- Walmart and other mass-retailer store brands.
- Amazon and e-commerce private labels.
- Perrigo and other OTC manufacturers.
- Generic drug companies supplying famotidine tablets.
- International manufacturers selling famotidine under local brands.
Private-label famotidine is the most direct threat because it offers the same active ingredient at a lower price. The absence of meaningful patent protection makes switching easy for retailers and consumers.
Therapeutic competitors
The strongest non-famotidine competitors are Kenvue’s own category rivals, including PPI brands such as Prilosec OTC and Nexium 24HR, as well as antacid brands such as Tums. This creates substitution risk across treatment classes rather than only between brands.
Pepcid’s response has been to maintain a broad product architecture: standard tablets, maximum-strength products, chewable formats, and combination products. Those extensions support shelf space and address different consumer preferences.
Are there Paragraph IV challenges against Pepcid AC?
Paragraph IV litigation is not a central risk for Pepcid AC. Paragraph IV certifications apply to abbreviated new drug applications that challenge patents listed for an approved reference drug in the Orange Book. A monograph OTC product such as Pepcid AC generally does not create the same Orange Book patent-challenge pathway as a protected prescription product.[4]
Generic famotidine competition therefore arises through ordinary ANDA or OTC monograph pathways, depending on the product and manufacturer’s regulatory strategy. There is no known active Paragraph IV campaign that threatens a remaining Pepcid AC exclusivity period.
What litigation and settlement agreements affect Pepcid AC?
No material current patent litigation or settlement agreement is central to Pepcid AC’s market position. The key legal disputes are more likely to involve:
- Trademark infringement.
- Trade dress and packaging.
- Advertising claims.
- Product liability.
- Manufacturing quality.
- Retail distribution and supply contracts.
Those disputes can affect individual products or channels but do not recreate molecule-level exclusivity for famotidine.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate rather than legal. Famotidine is a mature small molecule with established manufacturing processes and multiple global suppliers. The primary barriers are:
- FDA-compliant manufacturing capacity.
- Active pharmaceutical ingredient sourcing.
- Quality-control requirements.
- Supply-chain resilience.
- Packaging and labeling compliance.
- Retailer qualification.
- National distribution scale.
During demand surges, supply availability can temporarily favor the Pepcid brand. That advantage is operational, not patent-based. Competitors can enter when manufacturing capacity and regulatory compliance are available.
How does Pepcid AC compare with competing acid reducers?
| Factor |
Pepcid AC |
Generic famotidine |
PPI brands |
Antacids |
| Active ingredient |
Famotidine |
Famotidine |
Omeprazole, esomeprazole, lansoprazole |
Calcium carbonate and other antacids |
| Brand premium |
High relative to generic |
Low |
Often high |
Varies |
| Patent protection |
No material blocking protection |
None of practical significance |
Product-specific, mostly mature OTC brands |
Generally limited |
| Speed of relief |
Relatively rapid |
Comparable |
Slower onset |
Fastest |
| Duration |
Longer than simple antacids |
Comparable |
Long duration |
Shorter |
| Main buyer |
Intermittent heartburn user |
Price-sensitive user |
Frequent-heartburn user |
Episodic relief user |
| Main risk |
Private label and PPIs |
Commodity pricing |
Category switching |
Limited duration |
Pepcid AC’s strongest differentiation is not pharmacological superiority over generic famotidine. It is consumer trust, visibility, convenience, and perceived reliability.
What generic launch risks exist for Pepcid AC?
Generic launch risk is already realized. Generic and private-label famotidine products are established competitors, so future risk comes from further erosion rather than first entry.
The main scenarios are:
- Retailers increase private-label shelf space.
- Consumers trade down during inflationary periods.
- Online sellers expand low-price famotidine offerings.
- PPI products capture frequent-heartburn users.
- Retailers reduce branded facings in favor of higher-margin private label.
- Kenvue raises prices faster than the category.
Kenvue can mitigate these pressures through promotional pricing, product innovation, combination products, advertising, and retailer-specific packaging. These measures protect share but generally do not produce prescription-drug-style margins.
What is the geographic coverage of Pepcid AC?
The Pepcid brand has broad international recognition, but product names, regulatory status, formulations, and ownership arrangements vary by country. U.S. Pepcid AC is primarily an OTC retail brand. International markets may use different famotidine brands, local OTC classifications, or prescription-only controls.
Geographic commercial strength is likely highest in markets where:
- Famotidine is approved for nonprescription use.
- Large pharmacy and mass-retail channels exist.
- Consumers recognize the Pepcid name.
- Kenvue has established distribution.
- Heartburn self-treatment is common.
International protection is primarily trademark and regulatory-distribution based. The core famotidine patent estate does not provide meaningful geographic exclusivity in mature markets.
Key Takeaways
- Pepcid AC contains famotidine and is marketed in the United States by Kenvue.
- The product is an OTC monograph medicine, not a patent-protected prescription franchise.
- Famotidine’s core patent protection expired long ago.
- Pepcid AC has no material Orange Book exclusivity position.
- Paragraph IV litigation is not a central commercial risk.
- Generic and private-label famotidine create permanent price pressure.
- Ranitidine’s withdrawal increased famotidine demand, but the benefit was partly temporary.
- COVID-19-related demand was an exceptional event, not a durable indication.
- Kenvue does not disclose Pepcid AC revenue separately.
- Brand equity, retail distribution, packaging, and consumer trust are more important than patent rights.
- The principal financial risk is gradual branded-to-store-brand substitution, not a future patent cliff.
FAQs
Is Pepcid AC still patented?
The core famotidine composition and early product patents have expired. Current Pepcid AC sales are not protected by a molecule-level patent monopoly.
Can generic famotidine replace Pepcid AC?
Yes. Generic famotidine contains the same active ingredient and competes directly with Pepcid AC, subject to applicable FDA requirements and product labeling.
Does Kenvue disclose Pepcid AC sales?
No. Kenvue reports broader self-care and category results rather than standalone Pepcid AC revenue.
Is Pepcid AC approved for acid reflux disease?
Pepcid AC is labeled for heartburn and acid indigestion. OTC labeling does not make the product a general substitute for physician-managed treatment of persistent gastroesophageal reflux disease.
Did the ranitidine withdrawal permanently increase Pepcid sales?
The withdrawal created a major substitution opportunity for famotidine. It likely improved long-term category positioning, but the sharpest demand increase occurred during the initial withdrawal and supply-reallocation period.
References
-
U.S. Food and Drug Administration. (2024). DailyMed: Pepcid AC famotidine tablet labeling. National Library of Medicine.
-
Kenvue Inc. (2024). Annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Over-the-counter monograph M007: Antacid products. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (1995). FDA approves over-the-counter Pepcid AC for heartburn. FDA.
-
U.S. Food and Drug Administration. (2020, April 1). FDA requests removal of all ranitidine products from the market. FDA.
